The revised joint guidelines

Atherosclerosis Supplements

Volumn 1, Issue , 2000, Pages 3-7

  Faergeman, O ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Coronary heart disease; Guidelines; Lipid lowering; Prevention; Risk factors

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL; CHOLESTEROL;

ATHEROSCLEROSIS; BLOOD PRESSURE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; CONFERENCE PAPER; DIABETES MELLITUS; EUROPE; HEART INFARCTION PREVENTION; HUMAN; ISCHEMIC HEART DISEASE; LIFESTYLE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RISK MANAGEMENT; CORONARY ARTERY DISEASE; FEMALE; HEALTH BEHAVIOR; MALE; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; RISK FACTOR; STANDARD;

BLOOD PRESSURE; CHOLESTEROL; CORONARY DISEASE; DIABETES MELLITUS; FEMALE; GUIDELINES; HEALTH BEHAVIOR; HUMANS; MALE; RISK FACTORS;

EID: 0034280255     PISSN: 15675688     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(00)00561-X     Document Type: Conference Paper

References (20)

1. World Health Report, Report of the Director General, WHO, Geneva, 1998.
2. Pyörälä K., De Backer G., Graham I., Poole-Wilson P., Wood D. Prevention of coronary heart disease in clinical practice: Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur. Heart J. 15:1994;1300-1331.
3. Wood D, de Backer G, Faergeman O, Graham I., Mancia G, Pyörälä K, together with members of the Task Force: prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Atherosclerosis 1998;140:199-270.
4. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344(8934):1383-9.
5. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: cholesterol and recurrent events trial investigators. N Eng J Med. 335:(14):1996;1001-1009.
6. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339(19):1349-1357.
7. West of Scotland Coronary Prevention Study (WOSCOPS) Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998;97(15):1440-5.
8. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS: Air Force/Texas Coronary Atherosclerosis Prevention Study. J. Am. Med. Assoc. 279:(20):1998;1615-1622.
9. European Policy Group 1998. A desk-top guide to type 2 (non-insulin dependent) diabetes mellitus. International Diabetes Federation (Europe) 1998.
10. Pyrl K., Laakso M., Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab. Rev. 3:1987;463-524.
11. Yudkin J.S., Blauth C., Frury P., et al. Prevention and management of cardiovascular disease in patients with diabetes mellitus: an evidence base. Diabet. Med. 13:1996;S101-S121.
12. Laakso M. Dyslipidemia, morbidity, and mortality in non-insulin- dependent diabetes mellitus: lipoproteins and coronary heart disease in non-insulin-dependent diabetes mellitus. J. Diabetes Complicat. 11:(2):1997;137-141.
13. Haffner S.M. Management of dyslipidemia in adults with diabetes. Diabetes Care. 21:1998;160-178.
14. Prochaska J.O., DiClemente C.C., Norcross J.C. In search of how people change: applications to addictive behavior. Am. Psychol. 47:1992;1102-1114.
15. Ockene I.S., Houston Miller N. Cigarette smoking, cardiovascular disease, and stroke. Circulation. 96:1997;3243-3247.
16. Silagy C., Mant D., Fowler G., Lodge M. Meta-analysis of efficacy of nicotine replacement therapies in smoking cessation. Lancet. 343:1994;1454-1459.
17. De Lorgeril M., Renaud S., Mamelle N., et al. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet. 343:1994;1454-1459.
18. Burr M.L., Fehily A.M., Gilbert J.F., et al. Effects of changes in fat, fish and fibre intakes on death and myocardial re-infarction: diet and re-infarction trial (DART). Lancet. ii:1989;757-761.
19. Singh R.B., Rastogi S.S., Verma R., et al. Randomized controlled trial of cardioprotective diet in patients with recent acute myocardial infarction: results of one year follow up. Br. Med. J. 304:(6833):1992;1015-1019.
20. Fletcher G.F. How to implement physical activity in primary and secondary prevention: a statement for healthcare-professionals from the Task Force on Risk-reduction, American Heart Association. Circulation. 96:(1):1997;355-357.